Kingwu Financial News | In the afternoon, Kegi Pharmaceuticals (02171) expanded its gains. As of the time of publication, it rose by 27.27% to HK$6.02, with a turnover of 0.155 billion Hong Kong dollars.

The company announced that it will showcase the research data of Saikai Ze (Zevoclorin Injection), CT071, and CT0590 at the 66th American Society of Hematology Annual Meeting in the form of posters. The conference is scheduled to be held from December 7 to 10, 2024. The summaries of these products have been released on the ASH official website. The preliminary results of the CT0590 study indicate that the safety of the universal CAR-T cell therapy of CT0590 is controllable, achieving both deep and long-lasting clinical relief.